Traditional carrier screening assays are designed to look for only the most common mutations within a gene owing to cost considerations. Although this can yield high detection rates in specific populations for specific genes (such as cystic fibrosis in Caucasians), they are suboptimal for other ethnicities or for patients of mixed or unknown ethnic background. Next-generation DNA sequencing provides an opportunity to provide carrier screening using more comprehensive mutation panels that are limited primarily by information about the clinical impact of detected sequence changes. We describe a nextgeneration DNA sequencing-based assay capable of reliably screening patient samples in a timely and comprehensive manner. The analytic accuracy in a research setting has been documented. Here, we describe the additional studies performed to ensure the accuracy (analytic validity) and robustness of our assay for use in clinical practice and provide data from our experience offering this testing. Our clinical experience using this approach to screen 11,691 in vitro fertilization patients has identified 449 mutant alleles: 447 in carriers and 2 in an affected individual. In total, we found 87 distinct mutations in 14 different genes. Approximately one quarter of the mutations found are not included in traditional, limited, mutation panels, including 16 known mutations unique to our panel, and novel truncating mutations in several genes. (J Mol Diagn 2014, 16: 180e189; http://dx
Next-generation DNA sequencing (NGS) holds the promise of providing high-throughput, accurate carrier screening for multiple genes and multiple mutations in a highly efficient manner in clinical laboratories. 1 To date, NGS has found application in evaluating affected individuals for numerous multigene disorders and for elucidating the correct diagnosis and hence treatment of patients with various forms of cancer, 2 but carrier screening assay development has been slower because of concerns about accuracy 3, 4 and throughput in a clinical setting. Here, we describe the validation for clinical use of the first multigene carrier screening assay using NGS technology to be offered in the United States and provide information about our clinical experience thus far.
The genes included in our assay have proven clinical validity (the association between mutations in the gene and the related disorder has been established). 5, 6 In addition, carrier testing for these genes is recommended by the American College of Medical Genetics and Genomics, the American Congress of Obstetricians and Gynecologists, and/or are assessed routinely in persons of Ashkenazi Jewish descent because of the increased carrier frequency in this population and/or their clinical severity. The NGS panel validated the following diseases (gene symbols are shown in parentheses): Canavan disease (ASPA), cystic fibrosis (CFTR), glycogen storage disorder type 1a (G6PC), Niemann-Pick disease (SMPD1), Tay-Sachs disease (HEXA), Bloom syndrome (BLM ), Fanconi anemia C (FANCC ), familial hyperinsulinism (ABCC8), maple syrup urine disease type 1A (BCKDHA) and type 1B (BCKDHB), Usher syndrome type III (CLRN1), dihydrolipoamide dehydrogenase deficiency (DLD), familial dysautonomia (IKBKAP), mucolipidosis type IV (MCOLN1), and Usher syndrome type 1F (PCDH15). Additional genes and mutations, for which the gene or mutations are not readily evaluated by NGS, are assessed by alternate methodologies to ensure detection of clinically important mutations. The validations for these alternate methodologies followed standard, clinical laboratory procedures and are not described here.
Clinical carrier screening assays traditionally have assessed a limited set of mutations, typically those prevalent in specific ethnic groups. NGS provides the possibility of finding a much larger set of sequence variants across many ethnic groups. Because NGS is not limited to a small number of mutations, there is an additional dilemma related to the interpretation and reporting of the variants detected. Certainly, this is one of the most challenging areas associated with the advent of NGS technology in the carrier screening arena. Extensive discussions and feedback from our clinical and genetic counselor advisory boards has indicated that specificity was an important factor in offering carrier screening using NGS. In addition, others advocating a responsible approach to offering full sequencing recommend reporting only those variants that are known to have a clinical impact 7 (ie, no variants of unknown significance). After determination of the panel of genes to be assessed, it was essential to our clinical approach to rigorously establish the variants that must be detected for multifold reasons, including the following: i) to complete a comprehensive evaluation of all available information about each variant for each gene to determine the full list of mutations that were considered pathogenic; ii) to put this information into a variant database that could be curated, managed, and updated periodically to ensure that new information about variants could be added and that the panel would remain pertinent (this information then can be used for future cases); iii) to have a system that would integrate with the NGS data analysis pipeline to ensure rapid and consistent calling of clinically relevant mutations; and iv) to ensure that all variants that passed our filters for being pathogenic and clinically important could be either readily detected by the NGS assay or an alternate methodology to ensure detection. These alternate methodologies have all been used in clinical laboratories performing carrier testing for a number of years and hence are not discussed further (they were all validated before use in our laboratory).
This latter consideration is important and one that is gaining awareness among those using or considering using NGS technology for clinical applications. Some genes, gene regions, or mutations are particularly problematic for NGS and vary with the technology and analysis method(s) used. For example, pseudogenes, GC-rich regions, homopolymers, large deletions, and complex insertions/deletions all can be problematic depending on the specific sample preparation, sequencing, and analysis method(s) used. 8 Hence, our approach was to maximize the extent of what is addressable by NGS and to ensure detection of all clinically important mutations.
Because NGS has the ability to detect additional sequence variants in genomic regions sequenced at high quality and depth, we established a pathway for assessment of novel, reportable variants whereby a patient's DNA sequence is scanned for variants that meet one or more of the following criteria: i) occurs at a conserved donor or acceptor splice site (AE2 bases of intron), ii) generates a premature stop codon (nonsense mutation), or iii) generates a frame-shift in the protein sequence. When a stop codon or frame-shift mutation is present, the position of the mutation relative to the 3 0 most truncating mutation previously described for the disorder also is taken into account. These mutations are reported as predicted to be pathogenic and further increase the detection rates for each disorder beyond what has been reported previously as pathogenic.
Before beginning the validation of the clinical NGS assay, it was necessary to define acceptable analytic sensitivity and specificity criteria. To use an NGS assay for carrier screening, we required a high level of clinical confidence that the assay would not miss carriers. Hence, we were most concerned about the false-negative rate. All positive results were confirmed by Sanger sequencing, thereby eliminating false-positive results before clinical reporting. Studies detailing assay design and analytic accuracy in a research setting already have been described. 1 In brief, it was shown that NGS could achieve a false-negative rate of 2.52 Â 10 À4 (95% Wilson binomial confidence interval, 1.29 Â 10 À5 1.42 Â 10 À3 ) for single-nucleotide variants; a single false-negative call occurred in a sample previously characterized as aneuploid. 9 For insertions, deletions, or the more complex mutations that are indels, three false-negative results occurred. However, there were no false-negative results for any position in the sequence where a pathogenic mutation of interest occurred, as defined in our variant database, and/or that was not covered by an alternate methodology. Our goal therefore was to show a falsenegative rate of zero in the validation studies described later.
As mentioned earlier, in this study, Sanger sequencing was used as the comparator method for the analytic accuracy studies, despite the high cost and resource burden of fully sequencing each sample for each of the genes in the NGS panel. This can be leveraged for future validations.
For the purpose of clinical testing, it is necessary to be able to Sanger sequence any amplicon for any gene that is assessed by NGS to confirm the presence of the mutation, and therefore we also validated Sanger sequencing for approximately 250 amplicons.
To offer a clinical-grade carrier screening assay with high accuracy and precision (reproducibility), robustness, Carrier Screening Using NGS
The Journal of Molecular Diagnostics -jmd.amjpathol.orgthroughput, and a rapid turnaround time, it was necessary to complete a thorough validation. At the time our validation plan was set, there were no published guidelines on validation of NGS assays. Instead, we used a blended approach of professional society recommendations and the experience of the technical, clinical, and bioinformatics internal teams to devise an approach. Since completing these studies, one report 8 has been published that discusses the issues related to NGS assay validation, and a second publication 10 has offered recommendations that are aligned with our approach. In addition, the College of American Pathologists checklists, used by many clinical laboratories to monitor practices in support of accreditation, have been updated to include items specific to NGS assays (http://www.cap.org/apps/docs/laboratory_ accreditation/checklists/2012_checklist_brochure.pdf, last accessed July 27, 2013).
The clinical assay described in this article has been in use for more than 1.5 years. To date, we have screened more than 11,000 patients (from in vitro fertilization clinics across the United States) for carrier status, and found almost 500 carriers in 14 disease-causing genes. We also have identified seven novel variants, including one in CFTR. We outline our clinical experience with this assay later, and discuss the lessons learned and describe the mutations detected thus far in this cohort of patients.
Materials and Methods

Samples
Genomic DNA was purchased from the Coriell Cell Repositories (Camden, NJ) or isolated from whole blood by the Gentra Puregene method (Qiagen, Valencia, CA). DNA was quantitated using a NanoQuant Plate (Tecan, San Jose, CA).
Controls
Nuclease-free water (Sigma, St. Louis, MO) and two DNA controls, NA11284, which contains mutations in the CFTR gene (p.F508del/p.R560T), and NA00502, which contains mutations in the HEXA gene (c.1278insTATC/c.1421þ1 G>C), were purchased from Coriell Cell Repositories and were included in all runs.
Next-Generation DNA Sequencing
Next-generation DNA sequencing has been described previously. 1 Briefly, multiplex target capture using tiled, molecular inversion probes is followed by incorporation of molecular barcodes and Illumina (San Diego, CA) sequencing adapters. The product then is sequenced using the Illumina Hiseq2000 system. Data analysis proceeds using a combination of opensource and internally developed tools for sample demultiplexing, read alignment, genotype calling, and functional annotation. Subsequently, additional quality metrics are applied at the assay, sample, and variant levels, and nonreference calls are filtered using an in-houseedeveloped database of variants.
Reagents and Equipment
Details of reagents and equipment used for the validation studies are provided in Supplemental Tables S1 and S2 .
Quality Scores for Data Analysis
Three different types of quality scores were used to assess data in this validation: sample quality scores are indicative of the overall quality of a given sample's data, whereas the run quality scores are indicative of the overall quality of a run's data. Variant quality scores were used to assess sample-specific variant calls. Data that did not pass run or sample quality score criteria were marked as a "failed analysis" and were not evaluated further.
Sample Quality Scores
Sample quality score 1 (SQS1) is a fraction of callable bases: a genomic position is defined as "callable" if the call for this position passes multiple quality filters including having a depth greater than 50. The fraction of callable bases is the number of bases considered callable in the sample divided by the number of bases targeted by the assay. It is also the number of bases that pass both QS1 and QS2 thresholds (see variant quality scores, later). The threshold is 0.9 (90% of captured bases are callable). In clinical practice, any sample with less than 99% of bases callable is repeated to obtain a more complete sequence.
SQS2 is the number of uncallable variant database entries, that is, the number of Good Start Genetics, Inc. (GSG) variant database entries that were not callable for a given sample. The threshold is 10 (of 981) uncallable database positions. In clinical practice any uncalled position is sequenced by Sanger methodology.
Run Quality Scores
The run quality score 1 (RQS1) is the number of samples failing SQS1 or SQS2. The threshold is 20; RQS2 is the number of discordant genotype calls for control 1 (NA11284), the threshold is 0; RQS3 is the number of discordant genotype calls for control 2 (NA00502), the threshold is 0; RQS4, 5, and 6 are related to the detection of sample contamination from unexpected molecular barcodes, library barcode sequence cross-over rate, and mapped negative control reads, respectively; and RQS7 is the number of samples with zero associated reads, the threshold is 1.
Variant Quality Scores to Determine Callability
To identify low-confidence calls, we used thresholds on two quality scores (statistics) associated with each genotype call. These were depth of coverage (QS1) and strand bias (QS2). Thresholds for each of these parameters have been set empirically using data from previous analytic studies. 1 Any genotype call with a genomic position in the variant database jmd.amjpathol.org -The Journal of Molecular Diagnostics that does not meet these criteria is flagged as uncallable for the sample under consideration.
Cross-Validation and Performance Statistics
When runs included set 1 samples (fully characterized in a previous study 1 ), data were subject to cross-validation analysis. All sequence changes that differed from reference, irrespective of the clinical relevance, were assessed. Runs were compared sample-by-sample. Each variant was given one of the following mutually exclusive labels: true positive if the variant was reported at the same genomic position with the same lesion (alternative sequence) in the same sample; false positive (FP) if the variant was detected at a given position and sample in the validation for clinical use data, but not in the previous study; and false negative (FN) if the variant was detected at a given position and sample in the previous study, but not in the validation for clinical use data. Each FP variant was subject to a manual review of next-generation sequence data (reads) and Sanger reference data (if available). Systematic sequencing artifacts that resulted in frequent FP variant calls were recorded and performance statistics were calculated for each run.
Sanger Sequencing
PCR primers were developed for each region of interest. Briefly, 30-mL reactions were conducted with 100 ng of genomic DNA, 1 U of AmpliTaq Gold (Applied Biosystems, Grand Island, NY), and 1 mmol of each PCR primer in a PCR mix containing 5% dimethyl sulfoxide (vol/vol), 1 mol/L betaine, 2.5 mmol/L magnesium chloride, 1 mmol/L dNTPs (total), and 1Â GeneAmp PCR Gold Buffer (Applied Biosystems, Brea, CA). Cycling conditions were as follows: 95 C for 10 minutes, 30Â (95 C for 30 seconds, 60 C for 30 seconds, 72 C for 30 seconds), 72 C for 10 minutes, and 8 C forever. PCR primers used were as described by Jones et al, 11 except M13 tails were removed. PCR products were purified using AMPure Beads (Beckman Coulter, Brea, CA), and chain termination bidirectional Sanger sequencing was performed on an ABI 3730xl according to standard protocols. Data were analyzed using mutation surveyor (SoftGenetics, State College, PA).
Results
Validation of a Carrier Screening Assay for Clinical Use
Two sets of samples were used for the clinical validation. Set 1 consisted of samples thoroughly characterized by Sanger sequencing during previous studies. 1 They consisted of a mix of HapMap/Human Variation Panel samples (to ensure representation of different ethnic groups) and samples containing known mutations for the genes of interest. A list of the set 1 samples is provided in Supplemental Table  S3 . A second set of samples, set 2, consisted of Coriell DNA with known mutation status, 10 DNA samples from external laboratories (known mutation status; various extraction methodologies), and 49 blood samples extracted at GSG. There was some overlap in the Coriell samples used between sets 1 and 2. A list of the set 2 samples is provided in Supplemental Table S4 . Overall, 221 unique samples were contained within sets 1 and 2.
The validation for clinical use ("clinical validation," subsequently referred to as "CV") for the NGS assay was performed as summarized in Table 1 . Each study is described in more detail later. All studies passed the RQS criteria.
The general acceptance criteria for these studies were as follows: i) all previously defined, clinically relevant mutations must be detected as expected (false-negative rate of zero at clinically relevant positions) for all samples that met the SQS1 and 2 criteria; ii) the number of failing runs must be one or less for the planned studies; iii) the overall sample fail rate (samples failing SQS1 or SQS2) must be <3% (with the exception of the limit of detection and temperature assessment studies). Additional criteria were applied when specified for each study described later. Note that false-positive Unless otherwise stated, reagent lot 1, operator 1, and instrument 1 were used. CV1-1 was used as the lot 1 run for comparison in reagent lot-to-lot studies. *Molecular inversion probes (MIPs) are phosphorylated as a batch before use, which generates a sub-lot. CV2-1 used the lot 1 MIPs but a different sub-lot (compared with CV1-1). CV2-2 used a completely new lot of MIPs. results were not considered from an acceptance criteria perspective because Sanger sequencing would be used in clinical practice to determine the true status. Therefore, the main concern was whether the amount of Sanger sequencing generated could be managed in the laboratory given resource constraints. This is discussed further later.
A summary of the expected versus observed results for all set 1 and 2 samples across all studies is provided in Supplemental Table S5 . False-positive results are not shown in Supplemental Table S5 because these were assessed by Sanger sequencing and hence would be corrected before clinical result reporting. All runs passed the RQS criteria and hence this acceptance criterion was met.
Accuracy (CV1-1 and CV1-2)
All set 1 and set 2 samples were run through the assay, in experiments CV1-1 and CV1-2, respectively. Assessing the accuracy data for all samples of known genotypes from a clinical perspective, all expected mutations were detected (ie, there were zero FNs). Therefore, our accuracy acceptance criteria were met.
In addition, all next-generation sequenced base positions (irrespective of clinical relevance) were assessed for each sample in the CV1-1 data set and were compared with their respective counterparts in the known sequence to assess the concordance and detection rates. This was possible because all samples were previously fully characterized, as noted earlier. In other words, all base positions in the sequence for each sample were compared for genotype concordance. There were no FN and nine FP variant calls. Hence, the genotype concordance met the acceptance criterion of 99.999%, as shown:
1 À 9 FP 6; 403; 266 callable bases Â 100%Z99:9998% ð1Þ
DNA Source
The primary purpose of the blood samples included in set 2 was to assess the overall quality and callability in samples extracted by our methodology versus the Coriell cell line DNA. The comparison of DNA source (blood or Coriell) using distribution of variant level parameters showed that there was no significant variation in quality distributions for depth of coverage (QS1, P Z 0.20), strand bias (QS2, P Z 0.59), or quality over depth (QS3, P Z 0.48) ( Figure 1) . P values were calculated using the Wilcoxon rank-sum test with continuity correction. Note that three reportable mutations were detected by NGS in the unknown blood samples (set 2); all three were confirmed with Sanger sequencing.
Precision/Reproducibility (CV6-1, CV6-2, and CV6-3) A subset of samples from set 1 were run in duplicate in a single assay (intrarun reproducibility). This same subset then was run on a separate day by the same operator using the same reagents and instruments (interrun reproducibility). The intrarun reproducibility study was replicated using a different instrument and operator (instrument and operator reproducibility). Note that although multiple samples can be processed simultaneously in an NGS run, validation studies require multiple runs to assess different conditions. Because the cost and time required for each run is high, it is necessary to find the most efficient manner possible to assess all required variables. Therefore, multiple parameters often were assessed in a run when possible and reasonable because of these cost constraints. This approach also is used for performing reagent prequalification; parameters subsequently are separated only when the assay parameters do not pass acceptance criteria.
The use of set 1 samples for this study permitted crossvalidation to previous data and showed zero FN results, therefore showing good precision of the assay. More information is provided in Table 2 , which provides a summary of the FP and FN results for each CV run containing set 1 samples. The raw true positive, FP, and FN values represent all sequence changes observed across all regions detected, irrespective of whether the sequence change was clinically significant. The reported FP and FN values are based only on positions that are considered clinically important. Note that for each run, some samples were not assessed because they failed the callability criteria (SQS1). One FN variant was observed, a deletion mutation BCKDHA c.861_868delAGGCCCCG, in CV runs CV2-2 and CV6-1. It was unclear if this was owing to the quality of the DNA sample or the variant itself. Because this variant is expected to exist at extraordinarily low frequency it was removed from the panel (a rare example of a mutation that was considered not frequent enough to warrant an alternate methodology for detection). Note that this variant, because it generates a frame-shift, could be detected and reported to the clinical laboratory directors via the novel reportable detection pathway.
An assessment of all runs for overall quality parameters is provided later and shows assay reproducibility. Quality score distributions were consistent across all runs (Figure 1 ). Variability as a result of differences in sample sizes and run conditions was within the expected range. True positive heterozygous substitutions provided a median allele ratio of 0.5 for all runs and variability was very low. As expected, the median allele ratio for insertions and deletions was lower (0.34), indicating a slight reference bias compared with substitutions. Variability was also higher for insertions and deletions ( Figure 2) . The three sets of distributions shown here indicate there is no real difference at the variant level for any of these three indicators of capture reaction and sequencing performance.
Lot-To-Lot Assessment for Critical Reagents (CV2-1 and CV2-2)
A subset of samples from set 1 were analyzed with a different vendor lot of each critical reagent or reagent mix (lot 2). The comparator lot (lot 1) was the reagent set used for the accuracy experiment (CV1-1) described earlier. Reagents designated as critical included all enzymes, dNTPs, primers and Illumina cluster kits, flow cells, and sequencing by synthesis kits. The molecular inversion probes used for the assay are phosphorylated as a batch before use; this generated a sublot. Two lot-to-lot runs therefore were completed; CV2-1 used molecular inversion probe lot 1 but a different sub-lot (phosphorylation), all other critical reagents were from lot 2. CV2-2 used reagent lot 1 but a new lot of molecular inversion probes (lot 2). Cross-validation to assess genotype concordance showed zero FN variants (those that are clinically relevant and those that are not) on both reagent lot runs.
Allowable Variability of Input DNA (CV4)
The purpose of this study was to determine the performance of a AE10% deviation from the optimal DNA input amount of 1.5 mg (the optimal DNA input amount was determined during the development process). All DNA for clinical testing is quantified before use in the NGS assay and an input of 1.5 mg DNA input quantity is targeted. We would expect the quantification error to be less than 10% in practice. A subset of samples from set 1 was assayed in at each of the following input amounts: 1.35 mg, 1.5 mg, and 1.65 mg. The results show that input DNA concentration has the expected marginal effect on callability (SQS1) (Figure 3 ). There were no FN variants for this run. All FP variants were systematic and were represented equally among the different DNA input amounts, indicating that sequencing errors were not affected by input DNA concentration.
Interfering Substances
Potential sources of interfering substances include bilirubin, hemoglobin, Na 2 EDTA, and triglycerides. However, previous For each cell, the value for assessment of substitutions is given first followed by the value for insertions and deletions in parentheses sample GM00649 BCKDHA c.861_868delAGGCCCCG.
TP, true positive. studies by other investigators have shown that DNA testing is not subject to interference from these substances (http://www. accessdata.fda.gov/cdrh_docs/reviews/K043011.pdf, last accessed May 1, 2013). In addition, because 49 blood samples were included in the accuracy assessment studies and 60 blood samples were included in the temperature assessment study, most or all of these substances were assessed. Note also that the extraction procedure yields high-purity DNA and that an assessment of the 260 of 280 ratio was obtained for each sample.
Temperature Assessment (CV5)
In general, samples for DNA testing are shipped overnight at ambient temperature and are not considered to be particularly sensitive to temperature. However, because NGS is a new technology in the clinical carrier screening field, we wanted to determine whether temperature extremes during the shipping process would impact the sample integrity. The temperature conditions were chosen based on data obtained from TempTales devices (Sensitech, Inc., Beverly, MA) that were shipped from two different locations during the summer months (Texas and California) using our shipping containers. These devices record temperature data every few minutes and the data obtained subsequently can be downloaded onto a PC. The data showed maximum temperatures of 110 C for 2 to 3 minutes. The extreme temperature conditions were selected to mimic worse-case scenarios.
Sixty blood samples were exposed to three different temperature conditions. Set A (20 samples) was subjected to three freeze/thaw cycles over a 24-hour period before extraction. Set B (20 samples) was stored refrigerated. Set C (20 samples) was exposed to 110 C for 8 hours, transferred to 80 C for 16 hours, and then stored refrigerated until extraction. The acceptance criteria were as noted earlier plus the assay and sample quality scores needed to be within established thresholds regardless of temperature exposure.
The results (Figure 4) show that the temperature treatments described do not reduce the percentage of callable bases. Interestingly, DNA extracted using external source material and protocols (Coriell) had significantly lower callability (SQS1 value) compared with DNA extracted from blood using our current protocol. Note that the fraction of bases callable (SQS1) is not the same as the average depth of coverage because the former is the fraction of bases sequenced above a given depth and therefore relates to the uniformity with which all targets within a sample are captured and sequenced, whereas the latter simply describes the average number of times each target base is sequenced. Hence, the depth between experiments can appear statistically indistinguishable, whereas SQS1 may appear different.
Blinded Accuracy/Internal Proficiency Assessment (CV7)
Eighty samples were chosen at random from sample sets 1 and 2, and their identity was hidden from the run operator and reviewer until all tests and results were complete. All expected mutations were detected and hence the acceptance criteria were met.
Expected Repeat Rate
An important component of our assessment of the readiness of the assay for clinical use, and an acceptance criterion, was the repeat rate per run. The amount of time needed to re-run a sample, and the cost of this technology can be problematic, (shown in red, orange, and yellow). The percent callability of samples with the blinded accuracy data, CV-7 (shown in green), which uses Coriell samples, is also shown as a comparator. jmd.amjpathol.org -The Journal of Molecular Diagnostics hence a very low repeat rate was desired. Adhering to strict DNA quantification criteria (as noted earlier) helps to reduce the repeat rate. An assessment of the repeat rate was based on the number of samples that failed either SQS1 or SQS2 and is shown in Table 3 . Overall, this met the acceptance criteria of less than 3% because the average percentage repeat rate was 1.86%. In addition, note that this average includes the limit of detection and temperature assessment studies. This rate is expected to be an upper bound for clinical operations because we already showed during the validation studies that DNA extracted from blood at our facility provided a superior performance compared with Coriell DNA. Our experience in clinical practice to date is a fail rate of less than 1%. (Note that sufficient sample typically is available to complete all testing, including any required repeats and confirmations.)
As stated previously, all positive results on NGS are assessed by Sanger sequencing. This therefore includes both FP and true-positive results. Obviously, the true-positive rate is fixed by the carrier rate for each disorder, but the FP rate is driven by assay quality. In the clinical validation studies described here, approximately 5% to 10% of samples that passed the sample quality thresholds were found to have one to two FPs.
Overall, all acceptance criteria were met for the validation studies: there were no run failures, the repeat rate was within preset limits, and there were no FN results after the removal of a rare mutation in BCKDHA that was detected inconsistently in a Coriell DNA sample of questionable integrity.
Experience with the Assay in Clinical Practice
Here, we report on the results of 11,691 cases from patients undergoing carrier testing in an in vitro fertilization setting. The repeat rate has been below that observed in the validation, as expected, and similar for the FP rate (the number of samples requiring Sanger assessment that do not have the mutation indicated). With regard to FP results, we saw a small number of systematic variants, all of which have been sequenced multiple times across many samples, and now readily are distinguished from true positives on the basis of their characteristic genomic position and sequence change.
The list of all mutations found for each gene assessed by NGS is provided in Supplemental Table S6 . A total of 87 distinct mutations in 14 different genes were found. Frequency is the number of instances of the mutation observed in our data. The two most frequent mutations were CFTR F508del (199 þ 1 compound heterozygote), and CFTR p.R117H in conjunction with c.1210-12T [7] (30 patients). The third most frequent mutation that was found in 26 patients was HEXAc.1274_1277dupTATC. All other mutations occurred in fewer than 10 patients (carrier frequencies discussed later).
The Test Status column in Supplemental Table S6 indicates whether the mutation was found only by the GSG screening panel, generally tested in expanded mutation panels, commonly tested in most panels, or a novel (ie, previously unreported pathogenic) variant we detected. Of note is the fact that commonly used mutation panels would have missed many of these mutations. This includes those indicated by either "GSG Only" or "Novel" in the Test Status column.
Seven novel mutations were found in seven patients. The novel mutations found included one in CFTR, c.1526delG, which was found in an Asian patient. This is remarkable because CFTR is an extremely well-studied gene with approximately 2000 mutations already known per the Hospital for Sick Children CFTR Mutation Database website (http://www.genet.sickkids.on.ca/StatisticsPage.html, last accessed May 26, 2013). The overall carrier frequency observed for cystic fibrosis in this data set is 1 in 30, as shown in Table 4 . This is likely the result of screening a broad range of ethnicities (Supplemental Table S6 ).
Other novel truncating mutations were found in G6PC, CLRN1, MCOLN1, ABCC8, BCKDHB, and IKBKAP. In addition, 16 unique mutations that were tested for only in our panel also were identified, representing 17 carriers. In total, 23 unique mutations and 24 carriers would not have been detected using any other carrier screening panel that is clinically available. Because of the high detection rates using our NGS technology, the calculated reproductive risk after testing both partners is typically very low. However, when one partner is found to be a carrier, our licensed genetics professionals are available to counsel patients and couples and provide information about options for subsequent testing, including testing with a standard panel, testing with the panel we have described here, or testing with full gene sequencing (with the inclusion of all detected mutations and variants), depending on what is available for the gene in question.
The carrier frequency for our patient cohort is shown in Table 4 . The highest carrier frequencies are cystic fibrosis, with a rate of 1 in 30, and Tay-Sachs disease, with a frequency of 1 in 93. The lowest carrier frequencies found were for MSUD, type A (1 in 2110), and Bloom syndrome (1 in 946), as expected.
Discussion
We have described a highly sensitive NGS-based assay system for carrier screening that offers many advantages over traditional genotyping methodologies, and shows high accuracy, precision, reproducibility, and robustness for clinical use. The assay performed with high veracity across all variables assessed and that are expected to be encountered in typical clinical operations. Although FP results are generated from the NGS assay, all are systematic novel (ie, previously unreported) variants that can be recognized as such by their quality parameters; in addition, follow-up evaluation by Sanger sequencing allows reporting of only true-positive results. The assay has comparable turnaround time (currently 10 to 14 days) with traditional genotyping methodologies. The assay reagent costs also are comparable with genotyping arrays, a technology that NGS could replace; however, at this time, the capital costs may be different.
One of the main goals of developing the NGS assay for clinical carrier screening was to provide assessment for disorders recommended by professional societies at much greater depth than possible with other methodologies. Rather than merely testing for a limited set of mutations, we assessed all known, clinically important, pathogenic mutations, as well as novel mutations that would be predicted to be pathogenic based on the type of sequence change (ie, nonsense, frame-shift, invariant splice site). Although other investigators have looked at sequencing multiple genes for carrier testing purposes in a research setting, 12 this has not been performed previously on a large set of samples in clinical practice. This study therefore provides a unique opportunity to better assess carrier status and mutation spectrum in a broader range of patients and ethnicities.
Our initial clinical experience using this approach to screen 11,691 in vitro fertilization patients has diagnosed 447 carriers consisting of 87 unique mutations in 14 different genes. The most frequently found variants were CFTR p.F508del, CFTR p.R117H, and HEXA c.1274_1277dup-TATC, which were found in 200, 37, and 26 patients, respectively (200 CFTR p.F508del includes the compound heterozygote). The remaining mutations occurred in fewer than 10 patients each.
From a carrier screening perspective, 3.8% of individuals tested were found to be carriers of one or more of the genes assessed by NGS. Note that this is a conservative number because additional tests with relatively high carrier frequencies also commonly are assessed by non-NGS technologies during carrier screening (eg, fragile X syndrome and spinal muscular atrophy) and not all NGS genes were ordered by the referring health care provider. Hence, when viewed from this perspective, carriers of significant genetic disorders are likely to occur in a mixed ethnic population at a rate of 1 in 20 to 1 in 25.
The carrier frequencies in our patient cohort are generally in agreement with the available literature and range from 1 in 30 for cystic fibrosis to 1 in 2110 for MSUD, type A. The 1 in 30 carrier frequency for cystic fibrosis is a little surprising given that we are testing a diverse ethnic population. We intend to assess this further once a larger cohort has been tested.
Importantly, approximately one quarter of the specific mutations we have found would have been missed by the more commonly used limited mutation panels, including 16 previously known mutations that were tested for only in our panel, and 7 novel truncating mutations we have discovered in the CFTR, G6PC, CLRN1, MCOLN1, ABCC8, BCKDHB, and IKBKAP genes. Failure to detect these variants would have resulted in 24 undiagnosed carriers because one of the mutations was found in 2 different individuals. In addition, we are seeing a spectrum of mutations across ethnic groups that likely would be challenging to detect with non-NGS technologies. These missed mutations could put carrier couples at increased risk of having a child with a costly and debilitating disease.
We are detecting common, rare, and novel mutations in a clinical setting, a significant number of which are not included in other carrier screening panels. We therefore have shown the power of NGS technology in a carrier screening setting for increasing carrier detection rates for a number of severe, prevalent, and guideline-recommended disorders, something that is particularly valuable in a diverse ethnic population such as now exists in the United States.
